Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
01
03
2022
accepted:
18
04
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Patients with progressive fibrosing interstitial lung diseases (fILD) have increased morbidity and mortality. Lung fibrosis can be associated with lung cancer. The pathogenesis of both diseases shows similarities, although not all mechanisms are understood. The combination of the diseases is challenging, due to the amplified risk of mortality, and also because lung cancer treatment carries additional risks in patients with underlying lung fibrosis. Acute exacerbations in fILD patients are linked to increased mortality, and the risk of acute exacerbations is increased after lung cancer treatment with surgery, chemotherapy or radiotherapy. Careful selection of treatment modalities is crucial to improve survival while maintaining acceptable quality of life in patients with combined lung cancer and fILD. This overview of epidemiology, pathogenesis, treatment and a possible role for antifibrotic drugs in patients with lung cancer and fILD is the summary of a session presented during the virtual European Respiratory Society Congress in 2021. The review summarises current knowledge and identifies areas of uncertainty. Most current data relate to patients with combined idiopathic pulmonary fibrosis and lung cancer. There is a pressing need for additional prospective studies, required for the formulation of a consensus statement or guideline on the optimal care of patients with lung cancer and fILD.
Identifiants
pubmed: 35747227
doi: 10.1183/23120541.00115-2022
pii: 00115-2022
pmc: PMC9209850
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: N. Kewalramani reports grants and nonfinancial support from CSL Behring outside the submitted work. Conflict of interest: C. Machahua has nothing to disclose. Conflict of interest: V. Poletti reports personal fees from Boehringer Ingelheim, Roche, AMBU and ERBE, outside the submitted work. Conflict of interest: J. Cadranel reports fees for participation on boards of experts for the development of cancer drugs from AbbVie, AZ, BI, BMS, Jansen, MSD, Novartis, Pfizer, Roche and Takeda. Conflict of interest: A.U. Wells reports personal fees and nonfinancial support from Boehringer Ingelheim, Bayer and Roche Pharmaceuticals, and personal fees from Blade, outside the submitted work. Conflict of interest: M. Funke-Chambour reports grants from Boehringer Ingelheim and Roche, and other support from MSD, outside the submitted work.
Références
Lung Cancer. 2011 Jan;71(1):70-4
pubmed: 20493578
Respirology. 2009 Jul;14(5):723-8
pubmed: 19659650
J Thorac Cardiovasc Surg. 2014 May;147(5):1604-1611.e3
pubmed: 24267779
Lung Cancer. 2021 May;155:120-126
pubmed: 33798901
Respir Med. 2014 Oct;108(10):1549-55
pubmed: 25175479
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Surg Oncol. 2001 Jan;76(1):53-7
pubmed: 11223825
J Clin Med. 2020 Mar 05;9(3):
pubmed: 32150840
Eur J Cardiothorac Surg. 2011 Feb;39(2):190-4
pubmed: 20598898
Eur Respir J. 2019 Sep 19;54(3):
pubmed: 31285305
Intern Med. 2011;50(2):77-85
pubmed: 21245629
Lancet Respir Med. 2017 Jan;5(1):72-84
pubmed: 27599614
Anticancer Res. 2015 Feb;35(2):1065-71
pubmed: 25667495
Radiat Res. 2018 Oct;190(4):396-403
pubmed: 30016220
Surg Today. 2018 Apr;48(4):404-415
pubmed: 29124429
Pulm Pharmacol Ther. 2017 Aug;45:1-10
pubmed: 28377145
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Am J Respir Crit Care Med. 2017 Aug 15;196(4):479-493
pubmed: 28661183
Clin Lung Cancer. 2018 Jan;19(1):e5-e9
pubmed: 28687482
Sci Rep. 2020 Jul 2;10(1):10900
pubmed: 32616870
Respir Med. 2007 Dec;101(12):2534-40
pubmed: 17870458
Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66
pubmed: 25245821
Clin Respir J. 2021 Mar;15(3):336-344
pubmed: 33197284
Eur Respir Rev. 2017 Jan 3;26(143):
pubmed: 28049126
Front Oncol. 2020 Jan 21;9:1550
pubmed: 32039023
Int J Chron Obstruct Pulmon Dis. 2019 Oct 04;14:2273-2281
pubmed: 31631997
Respir Investig. 2018 Jan;56(1):72-79
pubmed: 29325685
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):622-631
pubmed: 28581404
Eur J Pharmacol. 2018 Mar 5;822:199-206
pubmed: 29374548
Cell Signal. 2020 Jan;65:109432
pubmed: 31693876
J Thorac Oncol. 2011 Jul;6(7):1242-6
pubmed: 21623239
Int J Clin Oncol. 2012 Dec;17(6):534-41
pubmed: 23152005
Radiother Oncol. 2017 Sep;124(3):482-487
pubmed: 28774597
Lung Cancer. 2015 Nov;90(2):234-42
pubmed: 26314614
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
Ann Am Thorac Soc. 2019 Aug;16(8):1041-1051
pubmed: 30892054
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43
pubmed: 17585107
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
JAMA. 2021 Mar 09;325(10):962-970
pubmed: 33687470
Surg Today. 2020 Aug;50(8):905-911
pubmed: 32144483
Am J Respir Crit Care Med. 2019 Mar 1;199(5):622-630
pubmed: 30141961
J Clin Med. 2021 Nov 26;10(23):
pubmed: 34884264
Lancet Respir Med. 2017 Dec;5(12):968-980
pubmed: 29033267
Oncoimmunology. 2020 Sep 22;9(1):1824631
pubmed: 33457101
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(1):7-18
pubmed: 21086900
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
J Thorac Dis. 2018 Jun;10(6):3829-3844
pubmed: 30069384
Nephron Clin Pract. 2010;115(1):c17-20
pubmed: 20173345
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
BMC Pulm Med. 2019 Apr 2;19(1):72
pubmed: 30940113
J Pathol. 2018 Jan;244(1):25-35
pubmed: 28862766
Respiration. 2020;99(1):9-18
pubmed: 31554007
Cancer Res Treat. 2018 Apr;50(2):374-381
pubmed: 28494537
Int J Clin Oncol. 2019 Dec;24(12):1543-1548
pubmed: 31352631
Oncol Lett. 2012 Sep;4(3):477-482
pubmed: 23741246
ERJ Open Res. 2019 Dec 16;5(4):
pubmed: 31857992
Cancers (Basel). 2018 Aug 02;10(8):
pubmed: 30072613
PLoS One. 2018 Aug 16;13(8):e0202360
pubmed: 30114238
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Epidemiol. 2000 Feb 15;151(4):384-95
pubmed: 10695597
Lancet Respir Med. 2018 Feb;6(2):86-88
pubmed: 29241977
Ann Thorac Surg. 2016 Dec;102(6):1905-1910
pubmed: 27546601
Am J Pathol. 2003 May;162(5):1495-502
pubmed: 12707032
Eur Respir Rev. 2020 Nov 18;29(158):
pubmed: 33208483
J Cancer Res Clin Oncol. 2016 Aug;142(8):1855-65
pubmed: 27350261
Farm Hosp. 2016 Jun 01;40(4):316-27
pubmed: 27571499
Lancet Respir Med. 2020 May;8(5):453-460
pubmed: 32145830
Sci Adv. 2020 Jul 08;6(28):eaba1983
pubmed: 32832599
Thorac Cancer. 2020 Nov;11(11):3317-3325
pubmed: 32986306
Oncol Lett. 2017 Jul;14(1):944-950
pubmed: 28693256
Respir Investig. 2018 Jul;56(4):268-291
pubmed: 29980444
Surg Today. 2020 May;50(5):469-474
pubmed: 31773277
J Thorac Cardiovasc Surg. 2008 Nov;136(5):1357-63, 1363.e1-2
pubmed: 19026828
Eur J Cardiothorac Surg. 2012 Jun;41(6):e161-5
pubmed: 22504895
Gen Thorac Cardiovasc Surg. 2015 Mar;63(3):164-72
pubmed: 25352311
Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25
pubmed: 24696125
Mod Pathol. 2017 Jan;30(1):26-38
pubmed: 27586205
J Thorac Oncol. 2020 Dec;15(12):1935-1942
pubmed: 32858235
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Lancet Respir Med. 2021 May;9(5):476-486
pubmed: 33798455
Thorac Cancer. 2018 Jul;9(7):847-855
pubmed: 29782069
Respir Res. 2018 Oct 3;19(1):195
pubmed: 30285867
Lung Cancer. 2017 Jun;108:48-54
pubmed: 28625647
Pathol Int. 1999 Dec;49(12):1060-6
pubmed: 10632926
Semin Respir Crit Care Med. 2006 Dec;27(6):634-51
pubmed: 17195140
N Engl J Med. 2020 Sep 3;383(10):958-968
pubmed: 32877584
Lung Cancer. 2019 Aug;134:274-278
pubmed: 31182249
J Thorac Dis. 2018 Feb;10(2):799-807
pubmed: 29607151
Anticancer Res. 2015 Jul;35(7):4259-63
pubmed: 26124387
Respir Med. 2017 Aug;129:158-163
pubmed: 28732824
Int J Clin Oncol. 2014 Apr;19(2):266-73
pubmed: 23660786
J Surg Oncol. 2002 Sep;81(1):33-7
pubmed: 12210025
Respirology. 2021 Feb;26(2):180-187
pubmed: 33145926
Ann Thorac Surg. 2020 May;109(5):1512-1520
pubmed: 31982443
Respir Investig. 2019 Nov;57(6):512-533
pubmed: 31377122
Anticancer Res. 2015 Mar;35(3):1697-701
pubmed: 25750330
Respir Res. 2016 Jul 22;17(1):90
pubmed: 27450274
Respir Investig. 2021 Jan;59(1):106-113
pubmed: 33004286
Lab Invest. 2002 Oct;82(10):1335-45
pubmed: 12379768
Eur Respir J. 2015 May;45(5):1434-45
pubmed: 25745043
Pulm Pharmacol Ther. 2020 Feb;60:101880
pubmed: 31874284
Cancer Sci. 2019 Dec;110(12):3738-3745
pubmed: 31608537
Am J Epidemiol. 2015 Apr 1;181(7):532-40
pubmed: 25693770
Radiother Oncol. 2017 Jul;124(1):1-10
pubmed: 28666551
Lancet. 2021 Oct 16;398(10309):1437-1449
pubmed: 34499865
Sci Rep. 2021 Apr 15;11(1):8312
pubmed: 33859288
Chest. 2015 Jan;147(1):157-164
pubmed: 25166895
Acta Pathol Jpn. 1987 Jan;37(1):11-9
pubmed: 3033984
Drug Saf. 2020 Oct;43(10):971-980
pubmed: 32734423
BMC Pulm Med. 2019 Aug 14;19(1):149
pubmed: 31412851
Eur Respir Rev. 2021 Oct 20;30(162):
pubmed: 34670806
Histopathology. 2017 Nov;71(5):725-735
pubmed: 28556957
Lung Cancer. 2019 Dec;138:65-71
pubmed: 31654836
J Thorac Dis. 2018 May;10(Suppl 13):S1547-S1555
pubmed: 29951305
Sci Rep. 2021 Jan 28;11(1):2596
pubmed: 33510351
Anticancer Res. 2010 Oct;30(10):4357-61
pubmed: 21036764
Anticancer Res. 2012 Dec;32(12):5475-80
pubmed: 23225454
Pathology. 2012 Apr;44(3):192-8
pubmed: 22406480
Int J Mol Sci. 2019 Jan 30;20(3):
pubmed: 30704051